Time Period Covered August 12, 2020 - August 12, 2020
Worldwide, there have been over 20.4 million reported cases and more than
742,000 deaths attributed to COVID-19. On August 11, Russia registered the
world’s first coronavirus vaccine, Sputnik-V, developed by the Gamaleya
Institute based in Moscow. However, since the vaccine has not completed
three phases of trials, there are many concerns over its safety and
effectiveness. Furthermore, Russia has released no scientific data on the
vaccine research conducted to date, furthering a lack of transparency about
how the vaccine works. Other closely monitored vaccines candidates include
one from the University of Oxford and AstraZeneca and one from Moderna and
the US National Institute of Health. Both have shown promising results in
published papers and are currently undergoing phase 3 studies.
Over the past weeks, the World Health Organization (WHO) has been adding
functionality to its COVID-19 global dashboard, to display all of the latest data
that have been published in the daily situation report; these data are now fully
available on the dashboard. Important narrative updates are being merged
into the WHO COVID-19 “Rolling updates” pages. Starting next Monday, 17
August, the daily situation report will be replaced by a “COVID-19 Weekly
Epidemiological Update” which will focus on analysis and interpretation of the
evolving epidemiologic situation. Operational updates will continue to be
shared through the “Weekly Operational Update on COVID-19” (WHO
Situational Report 203)
WHO spokesman said on Tuesday (August 11) that WHO and Russian health
authorities are discussing the process for possible WHO prequalification for its
newly approved COVID-19 vaccine. He also stated that prequalification of any
vaccine includes the rigorous review and assessment of all required safety and
efficacy data. Meanwhile, Russian President Vladimir Putin said on Tuesday that
Russia had become the first country in the world to grant regulatory approval
to a COVID-19 vaccine after less than two months of human testing